Olatec Therapeutics LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Olatec Industries LLC (to 2016)
0
Ending by 2030
Dec 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for Method for treating skin inflammatory diseases (US 9,078,869) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Feb 25, 2027The maintenance fee for Compounds for treating inflammation and pain (US 9,114,122) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 2 fees due Apr 6 to 15, 2027 · next Apr 6
- 2 fees due Jun 8 to 10, 2027 · next Jun 8
- 1 fee due Jul 2, 2027The maintenance fee for Methods for treating melanoma (US 11,857,529) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Method for treating multiple sclerosis (US 10,548,870) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Sep 8, 2027The maintenance fee for Method for treating contact dermatitis (US 9,278,082) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,476,316 | 3-methanesulfonylpropionitrile for treating inflammation and pain In force · From the USPTO record | In force | From the USPTO record | |
| US 8,829,046 | 3-methanesulfonylpropionitrile for treating inflammation and pain In force · From the USPTO record | In force | From the USPTO record | |
| US 8,975,297 | 3-Methanesulfonylpropionitrile for Treating Inflammation and Pain In force · Medium confidence | In force | Medium confidence | |
| US 9,492,420 | 3-methanesulfonylpropionitrile for treating inflammation and pain In force · From the USPTO record | In force | From the USPTO record | |
| US 9,770,428 | 3-methanesulfonylpropionitrile for treating inflammation and pain In force · From the USPTO record | In force | From the USPTO record | |
| US 10,080,735 | 3-methanesulfonylpropionitrile for treating inflammation and/or pain In force · From the USPTO record | In force | From the USPTO record | |
| US 10,500,184 | 3-methanesulfonylpropionitrile for treating inflammation and/or pain In force · From the USPTO record | In force | From the USPTO record | |
| US 11,229,620 | 3-methanesulfonylpropionitrile for treating inflammation and/or pain In force · From the USPTO record | In force | From the USPTO record | |
| US 8,802,885 | Process for preparing 3-methylsulfonylpropionitrile In force · From the USPTO record | In force | From the USPTO record | |
| US 9,024,056 | Crystalline Form of 3-Methylsulfonylpropionitrile In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 41: 2 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 3 abandoned · 3 no status recorded